Lightnews — Scholar-powered news

Mineralys Therapeutics

@mineralystx.com

45 followers 250 following 14 posts

We're a public, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for hypertension. mineralystx.com

Posts Media Videos Starter Packs

Mineralys Therapeutics @mineralystx.com · 7d

Our CEO spoke with @statnews.com about recent breakthroughs in understanding cardiovascular diseases and how targeting aldosterone could reshape #hypertension treatment.

Read the Q&A here: www.statnews.com/sponsor/2025...

#HighBloodPressure #CVD #CardioRenalMetabolic #MLYS

#CardioSky #NephSky

Can a new class of drugs finally control hypertension in millions of patients?

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors

www.statnews.com

Mineralys Therapeutics @mineralystx.com · 10d

Today we announced completion of enrollment in Explore-OSA, our Phase 2 #clinicaltrial examining the efficacy, safety & tolerability of lorundrostat in participants with #OSA & #hypertension. Topline results are anticipated in Q1 2026.

Read: ir.mineralystx.com/news-events/...

#CardioSky #NephSky

Mineralys Therapeutics Completes Enrollment in Phase 2 Explore-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Mineralys Therapeutics @mineralystx.com · 11d

Hypertension or high blood pressure affects 1.4B people globally. It’s the most prevalent & modiﬁable risk factor of cardiovascular diseases. In the U.S., 70M+ people aged 30–79 years have uncontrolled #hypertension.

#WorldHeartDay #HighBloodPressure ♥️

1 3

Reposted by Mineralys Therapeutics

WHO @who.int · 18d

New WHO report finds 1.4 billion people live with #hypertension.

Hypertension is the number one risk factor for:
‼️ Heart attack
‼️ Stroke

and can lead to:
‼️ Chronic kidney disease
‼️ Dementia

Get your blood pressure checked today! Learn more 👉 bit.ly/4nikP8v

Text reads: “7 in 10 people living with hypertension do not have it under control. Get your blood pressure checked today.”

29 100

Mineralys Therapeutics @mineralystx.com · 22d

In just 6 years, Mineralys advanced #lorundrostat, a potential first-in-class aldosterone synthase inhibitor, from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 2025.

Learn more: www.thepharmaletter.com/pharmaceutic...

#Innovation #MLYS

"Our vision is to lead in targeted therapies for aldosterone-driven cardio-renal-metabolic (CRM) disease. By targeting aldosterone dysregulation, we aim to meet a critical unmet need with a new mechanism in a field that has seen little innovation in over two decades."
-Jon Congleton
CEO of Mineralys Therapeutics

Mineralys Therapeutics @mineralystx.com · Sep 8

#HighBloodPressure #CKD #OSA #CardioSky #NephSky

Mineralys Therapeutics @mineralystx.com · Sep 8

Our CEO spoke with ThePharmaLetter about Mineralys’ clarity of purpose, long-term vision, & the clinical opportunities for lorundrostat to treat #hypertension and other aldosterone-driven conditions.

Read the interview: www.thepharmaletter.com/pharmaceutic...

#CardiovascularDisease

Q&A with Jon Congleton, CEO of Mineralys Therapeutics

An Executive Q&A with Jon Congleton, chief executive of fast-moving biopharma company Mineralys Therapeutics.

www.thepharmaletter.com

1 3

Mineralys Therapeutics @mineralystx.com · Sep 5

Dr. Manish Saxena is presenting new subgroup analyses from our Launch-HTN trial of lorundrostat at the American Heart Association Hypertension Scientific Sessions.

Details: ir.mineralystx.com/news-events/...

#Hypertension25 #BloodPressure @ahascience.bsky.social

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Patients with High Unmet Medical Need

Mineralys Therapeutics @mineralystx.com · Sep 4

#HighBloodPressure #CardiovascularDisease #CKD #OSA #CardioSky #NephSky

Mineralys Therapeutics @mineralystx.com · Sep 4

Today we closed the sale of additional stock shares in our underwritten public offering, bringing total gross proceeds to $287.5M. Funds will support clinical development of lorundrostat, R&D and manufacturing, & pre-commercial activities.

Read: ir.mineralystx.com/news-events/...

#Hypertension

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

1 2

Mineralys Therapeutics @mineralystx.com · Aug 30

📌

Mineralys Therapeutics @mineralystx.com · Jun 30

Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting.

Read our press release to learn more: ir.mineralystx.com/news-events/...

#BloodPressure #Cardiology #Cardiosky #MLYS

PRESS RELEASE: Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

2 3

Mineralys Therapeutics @mineralystx.com · Jun 17

#MedSky #EndoSky #CardioSky #Nephsky

Mineralys Therapeutics @mineralystx.com · Jun 17

Today we announced positive topline results from our Phase 2 Explore-CKD trial evaluating the safety and efficacy of lorundrostat in subjects with #hypertension and comorbid chronic kidney disease (CKD).

Learn more: ir.mineralystx.com/news-events/...

#MLYS #chronickidneydisease #biotech

1 3

Mineralys Therapeutics @mineralystx.com · May 24

Today we presented detailed results from our pivotal Ph3 Launch-HTN trial at #ESH2025, reinforcing the promise of lorundrostat as a new treatment approach for aldosterone driven #hypertension.

Read our press release to learn more: ir.mineralystx.com/news-events/...

$MLYS #bloodpressure

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

2 3